Should I buy or sell NeuroSense Therapeutics stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for NeuroSense Therapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" NRSN shares. View NRSN analyst ratings or view top-rated stocks .

How have NRSN shares performed in 2024?

NeuroSense Therapeutics' stock was trading at $0.7850 at the beginning of 2024. Since then, NRSN stock has increased by 94.9% and is now trading at $1.53. View the best growth stocks for 2024 here .

Are investors shorting NeuroSense Therapeutics?

NeuroSense Therapeutics saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 63,700 shares, an increase of 81.5% from the March 15th total of 35,100 shares. Based on an average trading volume of 307,400 shares, the days-to-cover ratio is currently 0.2 days. Approximately 0.7% of the company's shares are short sold. View NeuroSense Therapeutics' Short Interest .

When is NeuroSense Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, June 6th 2024. View our NRSN earnings forecast .

When did NeuroSense Therapeutics IPO?

NeuroSense Therapeutics (NRSN) raised $13 million in an initial public offering (IPO) on Thursday, December 9th 2021. The company issued 2,000,000 shares at $6.00-$7.00 per share.

How do I buy shares of NeuroSense Therapeutics?

Shares of NRSN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:NRSN

NeuroSense Therapeutics (NRSN) Stock Price, News & Analysis

→ Could Bitcoin Literally FORCE This Crypto To Rocket Up? (From Paradigm Press) (Ad)

Free NRSN Stock Alerts

$1.53

-0.07 (-4.38%)

(As of 04/15/2024 ET)

Compare

Today's Range: $1.52
▼
$1.66
50-Day Range: $1.25
▼
$2.11
52-Week Range: $0.40
▼
$2.33

Volume: 71,787 shs
Average Volume: 289,067 shs
Market Capitalization: $20.92 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Get NeuroSense Therapeutics alerts:

Ad Market Moving Trends

Top 5 AI Stocks to Buy for 2024

5 Best AI Stocks to Invest In Investors are getting very rich in AI stocks right now. Wall Street legend is giving away the name and ticker of the little-known AI stock Wall Street is currently buying hand-over-fist.

Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"

About NeuroSense Therapeutics Stock (NASDAQ:NRSN)

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. Its lead product is PrimeC, an extended-release oral formulation of a fixed dose combination of ciprofloxacin and celecoxib for the treatment of amyotrophic lateral sclerosis. The company's preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel.

NRSN Stock Price History

30 days | 90 days | 365 days | Advanced Chart

NRSN Stock News Headlines

April 12, 2024 | finance.yahoo.com

NeuroSense to Present PARADIGM Data at the American Academy of Neurology Annual Meeting April 16, 2024

April 12, 2024 | prnewswire.com

NeuroSense to Present PARADIGM Data at the American Academy of Neurology Annual Meeting April 16, 2024

April 15, 2024 | Market Moving Trends (Ad)

Top 5 AI Stocks to Buy for 2024

April 10, 2024 | prnewswire.com

NeuroSense Announces Pricing of $4.5 Million Registered Direct Offering and Concurrent Private Placement

April 9, 2024 | markets.businessinsider.com

NeuroSense Joins With Lonza To Advance Neurodegenerative Disease Treatments; Stock Up In Pre-market

April 9, 2024 | prnewswire.com

NeuroSense Collaborates with Lonza to Identify Exosome-based Biomarkers, in order to Advance Neurodegenerative Disease Treatments and Diagnostics

April 7, 2024 | uk.investing.com

NeuroSense reports significant ALS trial results, year-end financials

April 5, 2024 | investorplace.com

NRSN Stock Earnings: NeuroSense Therapeutics Beats EPS for Q4 2023

April 15, 2024 | Market Moving Trends (Ad)

Top 5 AI Stocks to Buy for 2024

April 5, 2024 | finance.yahoo.com

NeuroSense Announces Year End 2023 Financial Results and Provides Business Update

March 23, 2024 | morningstar.com

NeuroSense Therapeutics Ltd NRSN

February 21, 2024 | finance.yahoo.com

NeuroSense Reports Additional Positive Results from its ALS Phase 2b PARADIGM Trial

February 21, 2024 | prnewswire.com

NeuroSense Reports Additional Positive Results from its ALS Phase 2b PARADIGM Trial

February 7, 2024 | finance.yahoo.com

NeuroSense Regains Compliance with NASDAQ Minimum Bid Price Rule

January 30, 2024 | finanznachrichten.de

NeuroSense Therapeutics Ltd: NeuroSense's ALS Drug Candidate Shows Promise In Recent Phase 2b Trial; More Milestones To Come In 2024

January 30, 2024 | finance.yahoo.com

NeuroSense’s (NASDAQ:NRSN) ALS Drug Candidate Shows Promise In Recent Phase 2b Trial; More Milestones To Come In 2024

January 9, 2024 | finance.yahoo.com

NeuroSense Recaps Positive 2023 Achievements Including Statistically Significant Slowing of Disease Progression in Phase 2b ALS Trial of PrimeC and Highlights Anticipated 2024 Catalysts

January 4, 2024 | finance.yahoo.com

NeuroSense Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders' Equity Requirement

December 19, 2023 | investing.com

Neurosense Therapeutics (NRSN) Earnings Dates & Reports

December 16, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Crispr Therapeutics AG (CRSP) and Neurosense Therapeutics Ltd. (NRSN)

December 14, 2023 | finance.yahoo.com

NeuroSense Reports New Data: Statistically Significant Clinical Efficacy in Phase 2b ALS Trial

December 8, 2023 | markets.businessinsider.com

Analysts Are Bullish on Top Healthcare Stocks: Neurosense Therapeutics Ltd. (NRSN), Cerevel Therapeutics Holdings (CERE)

December 6, 2023 | finance.yahoo.com

We're A Little Worried About NeuroSense Therapeutics' (NASDAQ:NRSN) Cash Burn Rate

December 5, 2023 | marketwatch.com

NeuroSense Therapeutics Sees Positive Safety Data in Phase 2 Trial for ALS Treatment, Shares Fall

December 5, 2023 | markets.businessinsider.com

NeuroSense Says Phase 2b ALS Trial Meets Primary And Secondary Endpoints

December 5, 2023 | msn.com

NeuroSense ALS candidate meets key study goals

December 5, 2023 | finance.yahoo.com

NeuroSense's Phase 2b ALS Trial Achieves Primary Safety and Tolerability & Secondary Clinical Efficacy Endpoints

See More Headlines

Receive NRSN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NeuroSense Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today: 4/15/2024
Next Earnings (Estimated): 6/06/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:NRSN
CUSIP: N/A
CIK: 1875091
Web: www.neurosense-tx.com
Phone: 972-9799-6183
Fax: N/A
Employees: 14
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($0.83)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-11,280,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -678.59%
Return on Assets: -207.30%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 0.84
Quick Ratio: 0.84

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($0.14) per share
Price / Book: -10.93

Miscellaneous

Outstanding Shares: 13,670,000
Free Float: 9,922,000
Market Cap: $20.92 million
Optionable: Not Optionable
Beta: 1.58

7 Stocks to Buy And Hold Forever

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

Mr. Alon Ben-Noon (Age 45)
Co-Founder, CEO & Director
Comp: $619k
Mr. Or Eisenberg (Age 43)
Chief Financial Officer
Comp: $378k
Dr. Ferenc Tracik M.D. (Age 60)
Chief Medical Officer
Comp: $513k
Ms. Hagit Binder (Age 46)
Chief Operation Officer
Dr. Niva Russek-Blum Ph.D. (Age 45)
Chief Technology Officer
Ms. Yael Barak (Age 54)
VP of Quality & Compliance
Ms. Keren Pushett
Head of HR
Mr. Eidan Loushi
C.R.A.

Key Competitors

View All Competitors

NRSN Stock Analysis - Frequently Asked Questions

Should I buy or sell NeuroSense Therapeutics stock right now?: 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for NeuroSense Therapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" NRSN shares.
View NRSN analyst ratings or view top-rated stocks.
How have NRSN shares performed in 2024?: NeuroSense Therapeutics' stock was trading at $0.7850 at the beginning of 2024. Since then, NRSN stock has increased by 94.9% and is now trading at $1.53.
View the best growth stocks for 2024 here.
Are investors shorting NeuroSense Therapeutics?: NeuroSense Therapeutics saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 63,700 shares, an increase of 81.5% from the March 15th total of 35,100 shares. Based on an average trading volume of 307,400 shares, the days-to-cover ratio is currently 0.2 days. Approximately 0.7% of the company's shares are short sold.
View NeuroSense Therapeutics' Short Interest.
When is NeuroSense Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, June 6th 2024.
View our NRSN earnings forecast.

When did NeuroSense Therapeutics IPO?: NeuroSense Therapeutics (NRSN) raised $13 million in an initial public offering (IPO) on Thursday, December 9th 2021. The company issued 2,000,000 shares at $6.00-$7.00 per share.
How do I buy shares of NeuroSense Therapeutics?: Shares of NRSN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:NRSN) was last updated on 4/15/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

NeuroSense Therapeutics (NRSN) Stock Price, News & Analysis

About NeuroSense Therapeutics Stock (NASDAQ:NRSN)

NRSN Stock Price History

NRSN Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

NRSN Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info